#122705
Re: Farmas USA
CBIO
Ponen precio de 6,5 al offering anunciado ayer.
offering of 4,615,384 shares of its common stock, offered at a price of $6.50 per share to the public. Additionally, Catalyst has granted the underwriters a 30-day option to purchase up to an additional 692,307 shares of its common stock. All of the shares in the offering are being offered by Catalyst. The offering is expected to close on or about June 22, 2020, subject to customary closing conditions.
Ponen precio de 6,5 al offering anunciado ayer.
offering of 4,615,384 shares of its common stock, offered at a price of $6.50 per share to the public. Additionally, Catalyst has granted the underwriters a 30-day option to purchase up to an additional 692,307 shares of its common stock. All of the shares in the offering are being offered by Catalyst. The offering is expected to close on or about June 22, 2020, subject to customary closing conditions.
The gross proceeds to Catalyst from this offering are expected to be approximately $30.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Catalyst. This amount assumes no exercise of the underwriters’ option.
Catalyst anticipates using the net proceeds from this offering for general corporate purposes, which may include research and development activities in its complement program, clinical and manufacturing activities for marzeptacog alfa and dalcinonacog alfa, other research and development activities, capital expenditures, selling, general and administrative costs, facilities expansion, and to meet working capital needs.
Raymond James & Associates, Inc. is acting as the sole book-running manager,
«Después de nada, o después de todo/ supe que todo no era más que nada.»